Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Cancer Research and Clinical Oncology
Published in: Journal of Cancer Research and Clinical Oncology 11/2004

01-11-2004 | Original Paper

The role of combined imaging in metastatic medullary thyroid carcinoma: 111In-DTPA-octreotide and 131I/123I-MIBG as predictors for radionuclide therapy

Authors: Zairong Gao, Hans J. Biersack, Samer Ezziddin, Timur Logvinski, Rui An

Published in: Journal of Cancer Research and Clinical Oncology | Issue 11/2004

Login to get access

Abstract

Purpose

The medical treatment of metastatic medullary thyroid carcinoma (MTC) is still questionable. The aim of this study was to evaluate a combined imaging protocol using 111In-DTPA-octreotide and 131I/123I-MIBG to decide whether targeted radiotherapy would be useful, and which radiopharmaceutical (90Y-DOTATOC or 131I-MIBG) would be more effective.

Methods

Eight patients (four men, four women; mean age 61 years) with metastatic MTC were included. Treatments were performed with 3,330 MBq 90Y-DOTATOC at 6-week intervals, or 11.1 GBq 131I-MIBG with a minimum interval of 3 months.

Results

The imaging procedure was positive in all eight patients: 111In-DTPA-octreotide imaging in five patients, 131I/123I-MIBG imaging in four patients. With respect to the number of metastatic lesions, MIBG imaging was less effective than octreotide. According to the results of combined imaging, we identified one patient to be treated with 90Y-DOTATOC, and three patients with 131I-MIBG. An overall antitumor effect was observed in all four patients, one with partial remission and three with stable disease. No relevant toxicity was observed.

Conclusions

The combined imaging can increase the detection rate of metastatic foci in patients with MTC and identify more patients for effective radionuclide treatment. The treatment with 90Y-DOTATOC or 131I-MIBG is well tolerated and may improve the fate of patients with metastatic MTC.
Literature
Abdelmoumene N, Schlumberger M, Gardet P, Roche A, Travagli JP, Francese C, Parmentier C (1994) Selective venous sampling catheterization for localization of persisting medullary thyroid carcinoma. Br J Cancer 69:1141–1144
Adams S, Baum RP, Hertel A, Schumm-Draeger PM, Usadel KH, Hor G (1998) Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings. Eur J Nucl Med 25:1277–1283CrossRefPubMed
Arslan N, Ilgan S, Yuksel D, Serdengecti M, Bulakbasi N, Ugur O, Ozguven MA (2001) Comparison of In-111 octreotide and Tc-99m (V) DMSA scintigraphy in the detection of medullary thyroid tumor foci in patients with elevated levels of tumor markers after surgery. Clin Nucl Med 26:683–688CrossRefPubMed
Baudin E, Lumbroso J, Schlumberger M, Leclere J, Giammarile F, Gardet P, Roche A, Travagli JP, Parmentier C (1996) Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med 37:912–916PubMed
Brunt LM, Wells SA Jr (1987) Advances in the diagnosis and treatment of medullary thyroid carcinoma. Surg Clin North Am 67:263–279PubMed
de Jong M, Krenning E (2002) New advances in peptide receptor radionuclide therapy. J Nucl Med 43:617–619PubMed
DeLellis RA, Rule AH, Spiler I, Nathanson L, Tashjian AH Jr, Wolfe HJ (1978) Calcitonin and carcinoembryonic antigen as tumour markers in medullary thyroid carcinoma. Am J Clin Pathol 70:587–594PubMed
Diehl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P, Lange H, Bredow J, Korber C, Grunwald F (2001) Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med 28:1671–1676CrossRefPubMed
Dralle H, Damm I, Scheumann GF, Kotzerke J, Kupsch E (1992) Frequency and significance of cervicomediastinal lymph node metastases in medullary thyroid carcinoma: results of a compartment-oriented microdissection method. Henry Ford Hosp Med J 40:264–267PubMed
Frank-Raue K, Raue F, Buhr HJ, Baldauf G, Lorenz D, Ziegler R (1992) Localization of occult persisting medullary thyroid carcinoma before microsurgical reoperation: high sensitivity of selective venous catheterization. Thyroid 2:113–117PubMed
Hanna FWF, Ardill JES, Johnston CF, Cunningham RT, Curry WJ, Russell CF, Buchanan KD (1997) Regulatory peptides and other neuroendocrine markers in medullary carcinoma of the thyroid. J Endocrinol 152:275–281PubMed
Hoefnagel CA (1994) Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumors. Eur J Nucl Med 21:561–581
Hundahl SA, Fleming ID, Fremgen AM, Menck HR (1998) A national cancer data base report of 53,856 cases of thyroid carcinomas treated in the U.S. 1985–1995. Cancer 83:2638–2648CrossRefPubMed
Kaltsas G, Korbonits M, Heintz E, Mukherjee JJ, Jenkins PJ, Chew SL, Reznek R, Monson JP, Besser GM, Foley R, Britton KE, Grossman AB (2001) Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab 86:895–902CrossRefPubMed
Krausz Y, Rosler A, Guttmann H, Ish-Shalom S, Shibley N, Chisin R, Glaser B (1999) Somatostatin receptor scintigraphy for early detection of regional and distant metastases of medullary carcinoma of the thyroid. Clin Nucl Med 24:256–260CrossRefPubMed
Kurtaran A, Scheuba C, Kaserer K, Schima W, Czerny C, Angelberger P, Niederle B, Virgolini I (1998) Indium-111-DTPA-D-Phe1-octreotide and technetium-99m (V)-dimercaptosuccinic acid scanning in the preoperative staging of medullary thyroid carcinoma. J Nucl Med 39:1907–1909PubMed
Kwekkeboom DJ, Reubi JC, Lamberts SW, Bruining HA, Mulder AH, Oei HY, Krenning EP (1993) In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab 76:1413–1417CrossRefPubMed
Kwekkeboom DJ, Bakker WH, Kooij PPM, Konijnenberg MW, Srinivasan A, Erion JL, Schmidt MA, Bugaj JL, de Jong M, Krenning EP (2001) [177Lu-DOTA0, Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med 28:1319–1325CrossRefPubMed
Lupoli G, Lombardi G, Panza N, Biondi B, Pacilio G, Lastoria S, Salvatore M (1991) 131I-meta-iodobenzylguanidine scintigraphy and selective venous catheterization after thyroidectomy for medullary thyroid carcinoma. Med Oncol Tumor Pharmacother 8:7–13PubMed
Lupoli G, Cascone E, Arlotta F, Vitale G, Celentano L, Salvatore M, Lombardi G (1996) Treatment of advanced medullary thyroid carcinoma with a combination of recombination interferon alpha-2b and octreotide. Cancer 78:1114–1118CrossRefPubMed
Marsh DJ, Learoyd DL, Robinson BG (1995) Medullary thyroid carcinoma: recent advances and management update. Thyroid 5:407–424PubMed
Oeberg K (1998) Advances in chemotherapy and biotherapy of endocrine tumors. Curr Opin Oncol 10:58–65PubMed
Oishi S, Sasaki M, Sato T, Hirota Y, Takahashi M (1986) Imaging and uptake mechanism of 131I-meta-iodobenzylguanidin in medullary thyroid carcinoma. Endocrinol Jpn 33:309–315PubMed
Oosterom R, Verleun T, Bruining HA, Hackeng WH, Lamberts SW (1987) Human medullary thyroid carcinoma in tissue culture: secretion of calcitonin and carcinoembryonic antigen. J Endocrinol Invest 10:117–121PubMed
O’Riordain DS, O’Brien T, Crotty TB, Gharib H, Grant CS, van Heerden JA (1995) Multiple endocrine neoplasia type 2b: more than an endocrine disorder. Surgery 118:936–942PubMed
Papotti M, Kumar U, Volante M, Pecchioni C, Patel YC (2001) Immunohistochemical detection of somatostatin receptor types 1–5 in medullary carcinoma of the thyroid. Clin Endocrinol (Oxf) 54:641–649
Raue F, Winter J, Frank-Raue K, Lorenz D, Herfarth C, Ziegler R (1989) Diagnostic procedure before reoperation in patients with medullary thyroid carcinoma. Horm Metab Res Suppl 21:31–34PubMed
Rufini V, Salvatori M, Garganese MC, Di Giuda D, Lodovica Maussier M, Troncone L (2000) Role of nuclear medicine in the diagnosis and therapy of medullary thyroid carcinoma. Rays 25:273–282PubMed
Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE (1992) A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 13:513–521PubMed
Szakall S Jr, Esik O, Bajzik G, Repa I, Dabasi G, Sinkovics I, Agoston P, Tron L (2002) 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med 43:66–71PubMed
Troncone L, Rufini V (1997) 131I-MIBG therapy of neural crest tumors. Anticancer Res 17:1823–1832PubMed
Waldherr C, Schumacher T, Pless M, Crazzolara A, Maecke HR, Nitzsche EU, Haldemann A, Mueller-Brand J (2001) Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using [90Y]-DOTA-D-Phe1-Tyr3-octrotide: a pilot study. Nucl Med Commun 22:673–678CrossRefPubMed
Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, Haldemann A, Mueller-Brand J (2002) Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC. J Nucl Med 43:610–616PubMed
Wang Q, Takashima S, Fukuda H, Takayama F, Kobayashi S, Sone S (1999) Detection of medullary thyroid carcinoma and regional lymph node metastases by magnetic resonance imaging. Arch Otolaryngol Head Neck Surg 125:842–848PubMed
Metadata
Title
The role of combined imaging in metastatic medullary thyroid carcinoma: 111In-DTPA-octreotide and 131I/123I-MIBG as predictors for radionuclide therapy
Authors
Zairong Gao
Hans J. Biersack
Samer Ezziddin
Timur Logvinski
Rui An
Publication date
01-11-2004
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 11/2004
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-004-0588-1

Other articles of this Issue 11/2004

Journal of Cancer Research and Clinical Oncology 11/2004 Go to the issue

Original Paper

Antisense Tcf inhibits the neoplastic growth of liver cancer cells

Original Paper

Alterations in gene expression associated with the overexpression of a splice variant of DNA methyltransferase 3b, DNMT3b4, during human hepatocarcinogenesis

Original Paper

Primary chemotherapy with doxorubicin and paclitaxel in patients with early breast cancer: final results of a multicenter phase II study

Original Paper

Expression and clinical significance of CD44V5 and CD44V6 in resectable colorectal cancer

Original Paper

Insulin resistance, its consequences for the clinical course of the disease, and possibilities of correction in endometrial cancer

Original Paper

Chemotherapeutic management of recurrent/metastatic uterine carcinosarcomas (malignant mixed mullerian tumors): time for a re-appraisal?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits